Parabilis Medicines, Inc.
PBLS Nasdaq
SEC CIK 1657677
Follow Parabilis Medicines
Weekly email: filings, results
Revenue, last quarter
$2.1M
Net income
−$44.5M
−32.9% vs same quarter last year
EPS, diluted
−$0.36
+98.3% vs same quarter last year
Operating cash flow
−$41.1M
−30.3% vs same quarter last year
Source: SEC XBRL filings · latest filing